LLBO Lifeline Biotech Inc (CE)

Lifeline Biotechnologies, Inc. (Pink Sheets:LLBO), a developer of innovative medical technology, today announced that it has appointed Dr. Louis Keith as president of First Warning Systems�, Inc. Jim Holmes, Lifeline�s CEO stated, that �Dr. Louis Keith has been appointed president of its subsidiary, First Warning Systems, Inc. Dr. Keith has extensive experience in the field of breast cancer and has been associated with Lifeline for many years. He has been involved and has assisted in directing the development and testing of the First Warning System� interpretive software. He was worked very closely with Dr. Reeves, founder of Lifeline and inventor of the First Warning System�, and with the engineers at Nanyang Technical University in achieving the current capabilities of the FWS interpretive software that is the basis for Lifeline�s recent patent filing.� Dr. Louis Keith is Emeritus Professor of Obstetrics and Gynecology at Northwestern University where he had taught more than 5000 medical students in a period of 29 years. Breast disease has long been a focus of his research interests, having initially worked closely with the French group who developed thermography for a period of years. He has written and lectured widely on the topic of early detection of tumor masses and co-edited a book with Michele Gauterie from Strasbourg. He also has collaborated for more than a decade with Dr. William Reeves who developed the First Warning System and published various papers with him on the importance of separating the physiologic changes which can be detected before morphologic changes which appear later in the mammogram. His particular point of view has stressed the difficulty of the clinician who feels an abnormality on the breast examination and the need for a physiologic test to help him/her determine what is the best course of action to protect the patient�s health interests. About Lifeline Biotechnologies, Inc: Lifeline Biotechnologies, Inc. is an innovative medical technology company that is focused on completing the development of the First Warning System�, which is designed to assist in the early detection of breast cancer. Of the approximately $138 billion spent on cancer each year, Lifeline could potentially save the healthcare industry billions of dollars annually, assuming the following are successfully completed: Clinical trials (if required) and filing and receiving a 510(k) from the FDA, and the product is successfully established in the marketplace. Lifeline competes in the money markets for funds to support the development of its product. The cost of funds, for early stage companies like Lifeline, are expensive and the terms have been, and may continue to be, dilutive. www.lbti.com Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing, successful development of the Company�s product and regulatory and shareholder approval for anticipated actions.